Navigation Links
TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments
Date:5/13/2008

the second half of 2008, to discuss the overall Phase III program.

-- Completed a Phase I multiple dose clinical trial of tezampanel that

demonstrated the compound to be safe and well-tolerated, supporting the

development of tezampanel in pain and non-pain indications that require

chronic dosing.

-- Completed dosing of up to 210 mg of NGX426 in a Phase I maximum

tolerated dose trial evaluating the oral prodrug of tezampanel.

Following completion of this trial TorreyPines intends to initiate a

multiple dose clinical trial of NGX426 to support the chronic dosing of

NGX426.

-- Pharmacokinetic data from the ongoing Phase I maximum tolerated dose

trial of NGX426 suggest that 90 mg of NGX426 results in blood levels of

tezampanel that the company believes will prove to be analgesic.

TorreyPines intends to initiate a study in a model of capsaicin-induced

pain to confirm the analgesic activity of NGX426 administered orally,

with data from this study expected by the end of year.

-- Initiated a Phase II study of NGX267 for the treatment of xerostomia,

or dry mouth, secondary to Sjogren's syndrome. Data from this study

are expected by the end of year.

-- Presented animal data on TorreyPines' proprietary gamma secretase

modulator (GSM) compounds at the Keystone Symposium on Alzheimer's

disease. The data demonstrated that TorreyPines' GSM compounds provide

a more selective mechanism than gamma secretase inhibitors.

TorreyPines is developing its GSM compounds as a potential treatment

for Alzheimer's disease.

-- Acquired from Johns Hopkins University the rights to intellectual

property related to the novel use of glutamate receptor antagonists,

including TorreyPines' compounds tezampanel and NGX426, for the

prevention and treatment of stroke
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. TorreyPines Therapeutics to Present at the JMP Securities Healthcare Focus Conference
2. TorreyPines Therapeutics to Present at BMO Capital Markets Focus on Healthcare Conference
3. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
4. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
5. Prime Therapeutics Receives TIPPS Certification
6. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
7. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
8. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
9. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
10. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
11. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, Dylan ... dresses, has excitedly released its collection of discounted prom ... to Percy, a senior spokesman of the company, the ... of this promotion is to expand the UK market. ... in several different colors, lengths, and styles: A-line strapless, ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas Sale, ... has chosen their best-selling lace wedding dresses, vintage bridesmaid ... season. , Now, BellasDress.com features popular women’s dresses, ... discount prices. The business hopes everyone can have a ... , “All our elegant products are made with exquisite ...
(Date:12/25/2014)... Woodland Hills, California (PRWEB) December 25, 2014 ... in her home in Woodland Hills, California after an ... Harris passed away on Christmas Eve evening in her ... battle with aggressive metastatic breast cancer. ... International for over forty years, she pioneered and championed ...
(Date:12/25/2014)... 2014 Recently, LunaDress.co.uk has updated its blog to ... accessories. Now, all of the models at LunaDress.co.uk come with big ... lifts the wedding veil can turn out to be a most ... wedding veil can always bring surprise to a wedding. On the ... to choose veils for a big day . , Going ...
(Date:12/25/2014)... News) -- The risk of burns from fires and ... to be extra cautious, an expert says. "Between ... increase in patients coming in with burns," said Dr. ... Firefighters Burn Center of Stony Brook University Hospital in ... joy, but if not careful, could quickly turn tragic," ...
Breaking Medicine News(10 mins):Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Don't Let Burns Mar Your Holidays 2
... the truth about deadliness of Alzheimer,s, report says , , ... medical officials often fail to record severe dementia as a ... This finding not only points to a lack of knowledge ... can be a deadly illness, it suggests that deaths due ...
... mom and preemie baby , , ... to get one live person out of this situation, and we ... , , (Photo: http://www.newscom.com/cgi-bin/prnh/20081209/SF50878 ... of neonatology at Lucile Packard Children,s Hospital at Stanford , ...
... ANTONIO, Dec. 9 The Texas office of Oaks ... II, a 35,000,square-foot medical office building at 3603 Paesanos ... just east of the intersection of Loop 1604 and,Northwest ... divides ownership of the building among the tenants, equity,investors ...
... plans, executive benefits and investment consulting services, announced that its award-winning ... — at just the touch of a button. , ... ... These new resources are in addition to Spanish language enrollment ...
... Biggest rise in cases and deaths coming in developing ... -- By 2010, cancer will be the leading killer ... than AIDS, malaria and tuberculosis combined. , Unless new ... with cancer by 2030, and 17 million cancer deaths ...
... pediatricians, Fatema Meah, M.D. became a doctor because she loves ... when she entered private practice, she was frustrated with how ... billing issues. Two months ago, she and her partner ... to return her attention to her patients -- Allied Pediatrics ...
Cached Medicine News:Health News:Dementia Often Missed as Cause of Death 2Health News:Dementia Often Missed as Cause of Death 3Health News:It's A Merry Christmas for Baby John After Mother Michelle's Life-Saving Transplant 2Health News:It's A Merry Christmas for Baby John After Mother Michelle's Life-Saving Transplant 3Health News:It's A Merry Christmas for Baby John After Mother Michelle's Life-Saving Transplant 4Health News:It's A Merry Christmas for Baby John After Mother Michelle's Life-Saving Transplant 5Health News:Oaks Development Group Closes on Third San Antonio Project 2Health News:Oaks Development Group Closes on Third San Antonio Project 3Health News: Newport Introduces More Resources for Spanish Speaking Plan Participants 2Health News:Cancer to Surpass Heart Disease as World's Leading Killer 2Health News:Cancer to Surpass Heart Disease as World's Leading Killer 3Health News:Cancer to Surpass Heart Disease as World's Leading Killer 4Health News:'Mega' Pediatric Group Allows Doctors to Focus on Patient Care as the Business Side of Private Practice Becomes More Difficult to Sustain 2Health News:'Mega' Pediatric Group Allows Doctors to Focus on Patient Care as the Business Side of Private Practice Becomes More Difficult to Sustain 3
(Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has announced ... Market" report to their offering. ... focuses on the developments in the self-monitoring blood glucose ... Reimbursement analysis and the effects of competitive bidding have ... SMBG meters have been performed, based on the various ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ... "Investment Analysis of the US Medical Device Sector ... http://photos.prnewswire.com/prnh/20130307/600769 This ... sector identifies the key trends and rationale for ... mergers and acquisitions. The study will ...
(Date:12/22/2014)... -- Cyberonics, Inc. (NASDAQ: CYBX ), a global ... epilepsy, today announced it will participate in the 33 rd ... 2015, in San Francisco . ... will speak at 11:00 AM Pacific Time.  A live audio ... the Investor Relations link on the Cyberonics home page at ...
Breaking Medicine Technology:US Self-monitoring Blood Glucose Market 2Investment Analysis of the US Medical Device Sector 2
... 5, 2011 Clinical Care Options (CCO), a ... for healthcare professionals, today announced the addition of ... searchable online point-of-care CME resource for specialists in ... which includes its own continuously updated comprehensive textbook, ...
... a world-leading developer and marketer of innovative medical technologies for ... wholly-owned subsidiary of ConvaTec Holdings UK Ltd, has acquired Farnhurst ... delivery of stoma and continence care products. ... and as a well-respected company in the home delivery business ...
Cached Medicine Technology:Clinical Care Options Announces Addition of ClinicalTrials.gov Database to CCO inPractice™ Point-of-Care Resource 2Clinical Care Options Announces Addition of ClinicalTrials.gov Database to CCO inPractice™ Point-of-Care Resource 3ConvaTec Announces Acquisition of Farnhurst Medical 2
Enzyme Immunoassay for the quantitative ( qualitative 0020, on request) determination of IgG Class antibodies to Rubella virus....
... use as a quality assurance reagent ... immunodeficiency virus type 1 (anti-HIV-1), antibody ... (anti-HTLV-I), antibody to hepatitis C virus ... antigen (anti-HBc), antibody to cytomegalovirus (anti-CMV), ...
... HBsAg assay is the second ... U.S. Food and Drug,Administration capable ... random,access format on the VITROS ... you can run an,HBsAg test ...
... Anti-HBs assay is the first,diagnostic hepatitis assay ... capable,of being run in a random access ... So now you,can run a hepatitis test ... assay is intended for,the qualitative in vitro ...
Medicine Products: